Effect of Dapagliflozin (Forxiga) on hepatic lipid content and microbiota in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus - Effect of Dapagliflozin (Forxiga) on hepatic lipid content and microbiota in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes mellitus

Tokai University0 个研究点目标入组 17 人开始时间: 2017年12月20日最近更新: 2024年4月1日

适应症

试验速览

暂无简介。

•1. Patient who have alcohol intake more than 210g/week ethanol for males or 140g/week ethanol for females. 2. Patients diagnosed viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, drug-induced liver disease, biliary disorder, shock liver, hemochromatosis, Wilson's disease, and alpha1-antitrypsin deficiency 3. Patients diagnosed hepatic cirrhosis 4. Patients with a history of diabetic ketoacidosis 5. Type 1 diabetes mellitus or secondary diabetes 6. Serious renal dysfunction (serum Cre 1.3mg/dl or eGFR<45ml/min/1.73m2) 7. Pregnancy or possible pregnancy and breast feeding 8. Patients who had cerebral stroke, cerebral infarction, urinary infection, or genital infection within 12 weeks before giving their consent 9. Patients who had myocardial infarction, angina pectoris or atrial fibrillation 10. Patient with inability to take the drug by mouse 11. History of hypersensitivity to any of the ingredients of the study drug 12. Patient with contraindications to the study drug 13. In addition, when principal investigator or researcher deems inappropriate as a study subject

发起方